Abstract:BACKGROUND AND PURPOSE: Hirudin variants are the most powerful thrombin inhibitors discovered to date, with a lower risk of bleeding than heparin. For anticoagulation, the C-termini of hirudin variants bind to the exocite I of thrombin. Anticoagulant effects of gene-recombinant hirudin are weaker than natural hirudin for the reason of lacking tyrosine O-sulfation at C-terminus.EXPERIMENTAL APPROACH: An integrative pharmacological study was carried out using molecular dynamic, molecular biological and in vivo and in vitro experiments to elucidate the anticoagulant effects of protein-engineered hirudins.KEY RESULTS: Molecular dynamic analysis showed that modifications of the C-termini of hirudin variant 1 of Hirudo medicinalis (HV1) and hirudin variant 2 of Hirudinaria manillensis (HM2) changed the binding energy of the C-termini to human thrombin. The study indicated that Asp61 of HM2 that corresponds to sulfated Tyr63 of HV1 is critical for inhibiting thrombin activities. Further, the anticoagulant effects of HV1 and HM2 were improved when the amino acid residues adjacent to Asp61 were mutated to Asp. These improvements were prolongation of the activated partial thromboplastin time, prothrombin time and thrombin time of human blood, and decreased K<sub>i</sub> and IC<sub>50</sub> values. In the in vivo experiments, mutations at C-termini of HV1 and HM2 significantly changed partial thromboplastin time, prothrombin and thrombin time CONCLUSION AND IMPLICATIONS: The study indicated that the anticoagulant effects of gene-engineered HM2 are stronger than gene-engineered HV1 and HM2-E60D-I62D has the strongest effects and could be an antithrombotic with better therapeutic effects.

Structural basis of RGD-hirudin binding to thrombin: Tyr 3 and five C-terminal residues are crucial for inhibiting thrombin activity

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

The NMR Solution Structure of Recombinant RGD-hirudin

Efficient targeted anticoagulant with active RGD motif.

1H NMR assignment and secondary structure of recombinant RGD-hirudin.

Tyrosine phosphorylation of recombinant hirudin increases affinity to thrombin and antithrombotic activity

Structure Study of Recombinant RGD-Hirudin by Vibrational and Circular Dichroism Spectroscopy

Molecular dynamic and pharmacological studies on protein‐engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis

Single Amino Acid Substitutions Dissociate Fibrinogen-Clotting and Thrombomodulin-Binding Activities of Human Thrombin.

Effect of Sulfotyrosine and Negatively Charged Amino Acid of Leech‐Derived Peptides on Binding and Inhibitory Activity Against Thrombin

[Fermentation, Purification and Identification of Recombinant RGD-Hirudin].

Construction of R_(33)G_(34)D_(35)X_(36-r)HV3 Mutant Library and Screening for Optimal Dual-Site Targeting Hirudin III

Expression, Purification, and Mass Spectrometric Analysis of 15N, 13C-Labeled RGD-hirudin, Expressed in Pichia Pastoris, for NMR Studies.

RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection

Functional expression of a thrombin exosite I inhibitor triabin in Escherichia coli and elucidation of the role of key residues in its inhibitory activity

Construction and Expression of Chimeric Antithrombotics with Hirudin and RGD Sequence

Effect of amino acids near the RGD sequence on binding activities between αIIbβ3 integrin and fibrinogen in the presence of RGD-containing synthetic peptides from elegantin and angustatin

Expression, Purification and Characterization of the Recombinant Hirudin Variant Iii in the Bacillus Subtilis

Construction and Activity Analysis of Fused Hirudin Peptide

Dual Inhibition of HY023016 Based on Binding Properties of Platelet Membrane Receptor Subunit Glycoprotein Ibα and Thrombin Exosites.

Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis